🇺🇸 FDA
Patent

US 9040061

Topical formulation for administering a compound

granted A61KA61K31/505A61K31/635

Quick answer

US patent 9040061 (Topical formulation for administering a compound) held by Rigel Pharmaceuticals, Inc. expires Mon May 21 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue May 26 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 21 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K31/505, A61K31/635, A61K47/10, A61K9/0014